210
Participants
Start Date
September 1, 2021
Primary Completion Date
December 27, 2022
Study Completion Date
December 27, 2022
Tirzepatide
Administered SC
Placebo
Administered SC
Beijing Tsinghua Changgung Hospital, Beijing
Siping Central People's Hospital, Siping
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Zhongshan Hospital, Fudan University, Shanghai
Huadong Hospital Affiliated to Fudan University, Shanghai
Shanghai Hospital of Traditional Chinese Medicine, Shanghai
The Fifth People's Hospital of Shanghai, Shanghai
Shanghai Minhang District Central Hospital, Shanghai
Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing
Changzhou No.2 People's Hospital, Changzhou
Wuxi People's Hospital, Wuxi
Affiliated Hospital of Nantong University, Nantong
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
The First People's Hospital of Hangzhou, Hangzhou
Huzhou Central Hospital, Huzhou
Ningbo First Hospital, Ningbo
The First Affiliated Hospital Chongqing Medical University, Chongqing
The First Affiliated Hospital of Nanhua University, Hengyang
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang
Zhujiang Hospital, Guangzhou
Shenzhen Second People's Hospital, Shenzhen
West China Hospital of Sichuan University, Chengdu
The First Affiliated Hospital of Xi'an Medical University, Xi’an
The First Hospital of Qinhuangdao, Qinhuangdao
The Second Hospital of Jilin University, Changchun
Eli Lilly and Company
INDUSTRY